Sonde Completes $16 Million Series A Financing Round to Advance Vocal Biomarker Technology


Sonde Health Inc. today announced the completion of a $16 million Series A financing round, including the issuance of $6 million in shares upon conversion of debt into equity.

BOSTON, 11 April 2019 –(BUSINESS WIRE)–Sonde Health Inc., a company developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced the completion of a $16 million Series A financing round, including the issuance of $6 million in shares upon conversion of debt into equity. The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany), with participation from MP Healthcare Venture Management, Inc. (the corporate venture capital arm of Mitsubishi Tanabe Pharma Corporation), Neoteny 4, LP, Canepa Healthcare, and founder PureTech Health. Sonde intends to use the proceeds from the financing to expand its capability across multiple health conditions and device types and to fund commercialization activities.

“At M Ventures we back exceptional science and technology entrepreneurs to bring potentially disruptive ideas to reality,” said Edward Kliphuis, investment director of new businesses at M Ventures. “Sonde’s best-in-class vocal biomarker technology, driven by a great founder team, is such a transformational idea, which has the potential to positively impact patient outcomes by fundamentally reimagining how mental and physical conditions are currently monitored and managed.”

Sonde’s proprietary technology is designed to enable a range of consumer devices, such as smartphones and smart speakers, to provide disease screening and management solutions based on acoustic analysis of seconds of voice. Sonde is working to create seamless universal access to accurate and timely health information, which has the potential to promote wellness and improve the timing and selection of a range of therapeutic interventions. This approach may enable the prevention and treatment of conditions ranging from depression and respiratory diseases to chronic diseases of aging.

“One of the oldest tools in our health care arsenal, the thermometer, is arguably still one of the most valuable because of its simplicity and widespread availability outside the clinical setting. Our longstanding vision has been to harness the health information present in billions of daily voice interactions to create a 21st century thermometer, or ‘vocometer’, that provides broad digital healthcare decision support needed to enable new models of precision and preventative medicine,” said Jim Harper, co-founder and chief operating officer of Sonde Health. “This financing round and the support of our new long-term partners allows us to accelerate the development of this groundbreaking technology and help deliver the positive impact it can have on an individual’s health and the healthcare system.”

About M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany. Its mandate is to invest in innovative technologies and products with the potential to significantly impact the company’s core business areas. From its headquarters in Amsterdam and offices in the US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early stage investing and company creation including the creation of spin-offs to leverage the company’s science and technology base. For more information, visit

About Sonde Health
Co-founded by PureTech Health (LSE: PRTC), Sonde Health is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions. Sonde’s proprietary technology works by sensing and analyzing subtle changes in the voice to create a range of persistent brain, muscle, and respiratory health measurements that provide a more complete picture of health in just seconds. To date, Sonde has collected voice and health data from over 10,000 subjects as part of the ongoing validation of its platform. These research and development data and activities are being accelerated to expand its proprietary technology into neurological, respiratory, and cardiovascular diseases as well as other health and wellness conditions. Sonde’s vocal biomarker program has demonstrated the potential to effectively screen and monitor for disease using information obtained from an individual’s voice on commonly-owned devices and it has the potential to fundamentally change the way mental and physical health is monitored and diagnosed.

Allison Mead Talbot
+1 617 651 3156

US media
Tom Donovan
+1 857 559 3397